FDA
-
-
-
-
-
-
-
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back
-
-
-
-
-
-
-
Pacira BioSciences faces generic challenge to EXPAREL pain drug
-
-
-
-
-
-
-
Pacira BioSciences partners with J&J MedTech to expand ZILRETTA reach
-
-
-
-
-
-
-
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
-
-
-
-
-
-
-
Pacira Pharmaceuticals (PCRX) PT Raised to $21 at JPMorgan
-
-
-
-
-
-
-
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
-
-
-
-
-
-
-
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

